BARitOne will escalate oropharyngeal dose only for MRI-defined non-responders
BARitOne uses on-treatment diffusion MRI to increase gross tumour dose from 65 to 73 Gy only in predicted non-responders.
Tag
oropharynx
FDG-PET-guided dose escalation did not improve control in advanced oropharyngeal and laryngopharyngeal cancers
Escalating metabolically active disease to 73.5 Gy did not improve locoregional control, disease-free survival, or overall survival versus 66 Gy.
Planning computed tomography radiomics predicted recurrence in human papillomavirus-positive oropharyngeal cancer
A multi-regional clinical-radiomics model reached an external-test area under the curve of 0.908 for 5-year recurrence prediction.
No isolated failures in omitted nodal regions with reduced elective irradiation for early oropharyngeal cancer
Definitive intensity-modulated radiotherapy alone achieved 93.0% three-year overall survival, with no recurrence solely within omitted prophylactic nodal regions.
Mid-treatment tumour shrinkage predicted survival in oropharyngeal cancer
Tumour volume reduction above 40% during radiotherapy was independently associated with improved overall survival in patients with oropharyngeal cancer.
Dose de-escalation improved patient-reported outcomes in early p16-positive oropharyngeal cancer
Reducing radiotherapy from 70 Gy to 60 Gy was associated with better one-year swallowing outcomes and lower acute toxicity in selected patients.
Concurrent chemotherapy improved progression-free but not overall survival in low-volume head and neck cancer
Concurrent chemotherapy improved progression-free survival without a significant overall survival benefit in early primary tumors with low-volume nodal disease.